Haleon plc: Transaction in own shares
13 September 2024: Haleon plc (the "Company" or "Haleon") today announces the purchase of the following number of ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under its share buyback programme announced on 1 August 2024 (the "Buyback Programme").
| Date of purchase: | 13 September 2024 |
| Number of Shares purchased: | 510,900 |
| Highest price paid per Share (p): | 393.0000 |
| Lowest price paid per Share (p): | 387.7000 |
| Volume weighted average price paid per Share (p): | 391.4392 |
Following the settlement of the above, the Company's registered share capital consists of 9,119,128,372 ordinary shares. This figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
In accordance with Article 5s(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:
http://www.rns-pdf.londonstockexchange.com/rns/2159E_1-2024-9-13.pdf
This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.
This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.
| Enquiries
|
| ||
| Investors | Media
| ||
| Sonya Ghobrial | +44 7392 784784 | Zoë Bird | +44 7736 746167 |
| Rakesh Patel | +44 7552 484646 | Gemma Thomas | +44 7985 175048 |
| Emma White | +44 7823 523562 | | |
| Email: corporate.media@haleon.com | |||
About Haleon
Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.